Faculty Collaboration Database

Reactive Infectious Mucocutaneous Eruptions (RIME) in COVID-19. WMJ 2023 Dec;122(5):368-371

Date

01/05/2024

Pubmed ID

38180926

Scopus ID

2-s2.0-85181850811 (requires institutional sign-in at Scopus site)

Abstract

Reactive infectious mucocutaneous eruptions (RIME) is a relatively novel terminology describing postinfectious mucocutaneous eruptions that usually affect 2 or more mucosal sites. To our knowledge, we describe the first case of RIME secondary to COVID-19 infection in an elderly 64-year-old immunocompetent male patient. This contrasts with previous case reports that have identified cases of RIME post-COVID-19 infection among the pediatric population and young adults. Our patient had characteristic mucosal involvement and required hospitalization and treatment with systemic steroids. This report also reviews the clinical features, treatment modalities, and outcome of RIME secondary to COVID-19 infection in other published case reports. We emphasize the need for further prospective studies to better elucidate the use of steroids in the management of RIME.

Author List

Farhan R, Salim S, Surani A

Author

Asif Surani MD Assistant Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Aged
Child
Humans
Male
Middle Aged
Prospective Studies
Steroids
Young Adult